Compare PRO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRO | NEO |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2007 | 1999 |
| Metric | PRO | NEO |
|---|---|---|
| Price | $23.25 | $11.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $24.54 | $12.56 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 10-27-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $351,682,000.00 | ★ $709,162,000.00 |
| Revenue This Year | $10.50 | $10.90 |
| Revenue Next Year | $10.86 | $9.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.92 | ★ 10.10 |
| 52 Week Low | $13.61 | $4.72 |
| 52 Week High | $29.84 | $19.12 |
| Indicator | PRO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 76.65 | 62.15 |
| Support Level | $23.06 | $11.59 |
| Resistance Level | $23.20 | $12.26 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 95.24 | 72.49 |
Pros Holdings Inc provides software solutions that optimize shopping and selling experiences for both business-to-business and business-to-consumer companies across industry verticals in more than nearly 80 countries. Its PROS Platform is designed to help businesses create, optimize and market available offers and handle orders through both first- and third-party digital channels. The firm generates key revenue form the United States of America, Germany, The rest of Europe, Africa, Asia-Pacific, and Middle East regions.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.